Biosimilars are a sub-category of biologic medicines5. They are follow-on or alternative versions of existing, originator or reference biologic medicines whose marketing exclusivity rights have expired5.
To be granted approval as a biosimilar by regulatory authorities, the product must undergo rigorous comparability analyses to prove it possesses similar quality, efficacy and safety to the reference biological medicine with which it has been compared5.